玻璃体腔注射康柏西普治疗高度近视黄斑脉络膜新生血管的疗效

Effect analysis of the intravitreal Conbercept in the treatment of choroid neovascularization of macular with high myopia

摘要:

目的：探究玻璃体腔注射康柏西普治疗高度近视黄斑脉络膜新生血管(CNV)的疗效。

方法：回顾性选取2017-06/2019-12我院眼科收治的因高度近视导致CNV的患者56例56眼作为研究对象，根据治疗方式分为对照组和观察组，对照组28例28眼行玻璃体腔注射雷珠单抗治疗，观察组28例28眼行玻璃体腔注射康柏西普治疗。末次治疗后随访3mo，记录患者眼压、最佳矫正视力(BCVA)及并发症发生情况，采用光学相干断层扫描(OCT)测定黄斑中心凹视网膜厚度(CMT)，采用OCT仪水平线性扫描测量CNV面积。

结果：治疗后两组患者BCVA均较治疗前改善，且观察组BCVA优于对照组(均P<0.05)。治疗后3mo两组患者眼压、CNV面积及CMT均较治疗前降低，且观察组改善情况优于对照组(均P<0.05)。随访期间，观察组并发症发生率(4%)低于对照组(18%)。

结论：玻璃体腔注射康柏西普治疗高度近视CNV疗效优于雷珠单抗，可有效改善BCVA，降低CMT，减少术后并发症，提高临床疗效。

Abstract:

AIM: To explore the effect of intravitreal conbercept in the treatment of chorionic neovascularization(CNV)of macular macula with high myopia.

METHODS: Totally 56 patients with high myopia caused by macular angiogenesis in our hospital were retrospectively selected as the research objects from June 2015 to December 2019. According to the treatment methods, patients were divided into the control group and the observation group. The 28 cases(28 eyes)of patients in the control group were treated with the intravitreous injection of Rayzumab, and 28 cases(28 eyes)of patients in the observation group were treated with intravitreal injection of conbercept. After the last treatment, the patients were followed up for 3mo to record the intraocular pressure, the best corrected visual acuity(BCVA)and the incidence of complications. Optical coherence tomography(OCT)was used to measure the thickness of macular fovea retinal(CMT), and horizontal linear scanning of OCT instrument was used to measure the CNV area.

RESULTS:After treatment, the visual acuity of patients in the observation group gradually increased, and the improvement of BCVA was significantly higher than that of the control group at the same time point(P<0.05). After 3mo of treatment, it showed that IOP, CNV area and CMT in the observation group were significantly reduced after the combined treatment, and the improvement was better than that in the control group(P<0.05). The incidence of complications in the observation group(4%)was significantly lower than that in the control group(18%).

CONCLUSION:The treatment of intravitreal conbercept injection for the high myopia CNV was superior to lucentis, which could improve clinical efficacy by increasing BCVA, reducing CMT thickness, improving vision and reducing postoperative complications.